Auriga Laboratories Announces FDA Approval Of Liquadd (TM) Oral Solution For The Treatment Of ADHD And Upcoming ... (Medical News Today)
Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the FDA approval of Liquadd (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL indicated for the treatment of Attention Deficit Disorder with Hyperactivity (ADHD). The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually.

Pipex Pharmaceuticals' Oral Flupirtine Opens IND With FDA For Phase II Clinical Trial For Fibromyalgia (Medical News Today)
Pipex Pharmaceuticals, Inc.

Non-invasive Bladder Testing - Laborie Medical Technologies Receives FDA 510(k) Clearance For Tetra(tm) Bladder ... (Medical News Today)
Urodynamix Technologies Ltd. (TSX-V:URO) announced that its worldwide distribution partner, Laborie Medical Technologies Inc. (Laborie) has obtained 510(k) clearance from the U.S. Food and Drug Administration to market their urodynamic equipment with the Tetra(tm) Bladder Monitor System for non-invasive bladder testing.